MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis

Area of Science:

• Immunology
• Vaccinology
• Parasitology

Background:

• An optimal leishmaniasis vaccine requires both CD4+ and cytotoxic CD8+ T cell responses.
• Leishmania infantum LACK antigen is a target for vaccine development.

Purpose of the Study:

• To compare DNA-LACK/MVA-LACK and DNA-LACK/VV-LACK prime/boost immunization strategies.
• To evaluate the induction of parasite-specific T cell responses and protection against Leishmania major infection in mice.

Main Methods:

• Heterologous prime/boost immunization using DNA and poxvirus vectors (MVA, VV) expressing LACK antigen.
• Assessment of CD4+ and CD8+ T cell responses, including IFN-gamma and TNF-alpha secretion.
• Evaluation of protection by measuring lesion size reduction and parasitemia after L. major challenge.

Main Results:

• DNA-LACK/MVA-LACK elicited higher CD8+ T cell responses compared to DNA-LACK/VV-LACK.
• Both CD4+ and CD8+ T cells were induced by the DNA-LACK/MVA-LACK protocol.
• DNA-LACK/MVA-LACK provided significantly greater protection (65-92% lesion reduction) lasting at least 17 weeks.

Conclusions:

• The DNA-LACK/MVA-LACK prime/boost strategy is superior to DNA-LACK/VV-LACK for inducing CD8+ T cell immunity and protection against cutaneous leishmaniasis.
• Modified vaccinia virus Ankara (MVA)-LACK is a safe and effective vector for leishmaniasis vaccine development.